Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple Sclerosis

This study has been completed.
Information provided by (Responsible Party):
University Hospital of North Norway Identifier:
First received: November 4, 2008
Last updated: September 2, 2011
Last verified: September 2011

Several studies have shown that bone mineral density (BMD) at the femoral neck decreases with increasing physical handicap (EDSS-score) in MS patients. Possible explanations are less weightbearing exercise or less UV-exposure resulting in reduced vitamin D generation in the skin. Prevention of osteoporosis is a high priority, because treatment of the established disease remains sub-optimal.

We have designed a double-blind randomised controlled trial of two years' duration including 90-100 persons with MS age 18-50 to assess whether supplementation with vitamin D, given as a weekly dose of 20,000 IU cholecalciferol, can prevent bone loss.

The primary objective of this study is to determine changes in BMD over the 2 year study period comparing treatment and placebo groups.

The most important secondary objective is to determine cytokine profiles in blood samples. We will also assess parameters related to vitamin D status and physical performance.

Condition Intervention Phase
Multiple Sclerosis, Osteoporosis
Dietary Supplement: cholecalciferol
Dietary Supplement: calcium carbonate
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Can Vitamin D Supplementation Prevent Bone Loss in Persons With MS? A Randomised, Placebo-controlled, Single-centre Study

Resource links provided by NLM:

Further study details as provided by University Hospital of North Norway:

Primary Outcome Measures:
  • Changes in BMD over the 2 year study period comparing treatment and placebo groups [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Cytokine expression following vitamin D supplementation [ Time Frame: 2 years ]
  • Contribution of vitamin D from different sources (generation in the skin, diet and supplements) to serum 25(OH) vitamin D (vitamin D status) [ Time Frame: 2 years ]
  • Changes in parameters of lower extremity function over the 2 year study period [ Time Frame: 2 years ]
  • The number of relapses, the time to first relapse, the number of relapse-free patients [ Time Frame: 2 years ]
  • The number of patients without progression of disability judged by EDSS and [ Time Frame: 2 years ]
  • Reported infections [ Time Frame: 2 years ]
  • Ratings on a fatigue scale [ Time Frame: 2 years ]

Estimated Enrollment: 80
Study Start Date: January 2008
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
cholecalciferol, calcium carbonate
Dietary Supplement: cholecalciferol
cholecalciferol capsules, 20,000 IU weekly for 2 years and calcium carbonate 500 mg daily
Other Name: Dekristol, Weifa-kalsium
Dietary Supplement: calcium carbonate
calcium carbonate 500 mg daily for 2 years
Other Name: Weifa-kalsium
Placebo Comparator: 2
capsules not containing cholecalciferol, otherwise identical to Active comparator; calcium carbonate
Dietary Supplement: calcium carbonate
calcium carbonate 500 mg daily for 2 years
Other Name: Weifa-kalsium


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 to 50 years
  • EDSS < 4.0 (able to walk without rest some 500 m)
  • Women have to be premenopausal
  • MS according to the McDonald criteria; prepared and considered able to follow the protocol; using appropriate contraceptive methods (women of childbearing potential)
  • Having given written informed consent.

Exclusion Criteria:

  • Pregnancy or unwillingness to use contraception; alcohol or drug abuse
  • Use of glucocorticoid treatment other than intravenous methylprednisolone for treatment of relapses
  • Known allergy to cholecalciferol or arachis oil (peanuts)
  • Therapy with digitalis, calcitonin, active vitamin D3 analogues, fluoride, or bisphosphonates during the previous 12 months
  • Any condition predisposing to hypercalcaemia
  • Nephrolithiasis or renal insufficiency
  • Presence of primary hyperparathyroidism, hyperthyroidism, or hypothyroidism in the year before the study began; a history of nephrolithiasis during the previous five years.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00785473

University Hospital of North Norway
Tromsø, Norway, 9038
Sponsors and Collaborators
University Hospital of North Norway
Principal Investigator: Margitta T Kampman, MD, PhD University Hospital of North Norway
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University Hospital of North Norway Identifier: NCT00785473     History of Changes
Other Study ID Numbers: MSvitD1
EudraCT 2006-00427-11
Study First Received: November 4, 2008
Last Updated: September 2, 2011

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Calcium, Dietary
Vitamin D
Calcium Carbonate
Bone Density Conservation Agents
Physiological Effects of Drugs
Growth Substances
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents processed this record on May 25, 2017